Lv3
270 积分 2022-11-10 加入
Ribociclib induced acute kidney injury: A case report
10个月前
已完结
Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS)
10个月前
已完结
Cyclin-dependent kinase 4/6 inhibitors as neoadjuvant therapy of hormone receptor-positive/HER2-negative early breast cancer: What do we know so far?
11个月前
已完结
Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis
11个月前
已完结
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
11个月前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
11个月前
已完结
Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2− breast cancer in Mexico
1年前
已完结
Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer
1年前
已完结
[Treatment of palbociclib in hormone receptor positive breast cancer: a real-world study and efficacy prediction model]
1年前
已完结
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System
1年前
已完结
皖公网安备34019202002308
